Lexicon Pharmaceuticals, Inc.
LXRX
$1.88
$0.000.00%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 93.28% | -21.63% | -492.62% | 112.86% | 25.09% |
| Total Depreciation and Amortization | -6.78% | -21.85% | -14.20% | 0.00% | 40.80% |
| Total Amortization of Deferred Charges | 37.58% | 23.13% | 0.00% | 0.25% | 0.00% |
| Total Other Non-Cash Items | -13.31% | -17.15% | 37.45% | 1,007.34% | 1,031.58% |
| Change in Net Operating Assets | -260.88% | 68.22% | -227.75% | 158.24% | -263.47% |
| Cash from Operations | 14.52% | 27.69% | -240.25% | 138.82% | -103.70% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -1,554.72% | -90.73% | 236.66% | -61.85% | -25.09% |
| Cash from Investing | -1,554.72% | -90.73% | 236.66% | -61.85% | -24.43% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -66.67% | -- | 100.00% | -- | -- |
| Issuance of Common Stock | 95,860.27% | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | 100.00% | -2,188.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 3,132.32% | -- | 100.00% | -7,767.13% | -450.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 124.55% | -154.18% | 325.90% | -232.38% | -111.74% |